The emergence of neoadjuvant immunotherapy has led to significantly higher PCR and EFS rates in patients with stage III NSCLC with negative driver genes,3 which prompts an interesting question: can immunotherapy combined with chemotherapy be used as neoadjuvant therapy in patients with stage III NSCLC with EGFR mutations? This evidence concerns the gene EGFR and non-small cell lung carcinoma.